Radioactive drug for advanced melanoma
Part of Cancer, Eyes & vision, Skin clinical trials.
This trial tests a new radioactive drug (A9-3408) for people with advanced melanoma that has not responded to standard treatments. The drug is designed to target and destroy melanoma cells. The study is early phase, so it is mainly checking safety and how well the drug works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your melanoma must be seen on a special PET scan (the study drug's tracer must light up your tumors).
- Your melanoma has spread or cannot be removed, and it has gotten worse after at least one standard treatment.
- You must be feeling well enough to do daily activities (ECOG 0-1).
- Your organs (like kidneys, liver, and bone marrow) must be working well.
- You cannot have had any other radioactive treatment before, and you must agree to use birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental drugs, AK104 or AK112, combined with a targeted therapy called axitinib for people with metastatic mucosal melanoma (a rare type of skin cancer that has spread). The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
This early-phase study tests two new radioactive treatments (lutetium-177 and actinium-225) together with a guided imaging agent in people with GRPR-positive solid tumors (including prostate, breast, or colorectal cancers). The goal is to see if these treatments can shrink tumors that have stopped responding to standard therapies.
This trial tests a new radioactive treatment, [225Ac]Ac-FL-020, for men with metastatic castration-resistant prostate cancer (mCRPC) that has gotten worse despite other treatments. It's for those who have had at least one prior hormone therapy or chemotherapy.
This early-stage study tests whether a targeted radioactive drug can shrink advanced melanoma, either alone or along with nivolumab (an immune-activating medicine). You may be eligible if your melanoma shows a specific target on scan imaging and has progressed despite prior melanoma treatments.
This study tests an experimental radioactive drug ([225Ac]Ac-PSMA-XT) that targets prostate cancer cells. It is for men whose prostate cancer has spread and stopped responding to standard hormone therapy and chemotherapy.
This trial tests a new radioactive drug (225Ac-FAPI-XT) for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called FAP found on many cancer cells, which may help deliver radiation directly to the tumor.
Hear when a new Mucosal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.